
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3505443/publications.pdf Version: 2024-02-01



FARIEN REVAL

#	Article	IF	CITATIONS
1	Rab27a Supports Exosome-Dependent and -Independent Mechanisms That Modify the Tumor Microenvironment and Can Promote Tumor Progression. Cancer Research, 2012, 72, 4920-4930.	0.9	527
2	High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer. Nature Genetics, 2019, 51, 1060-1066.	21.4	335
3	MicroRNA Sequence and Expression Analysis in Breast Tumors by Deep Sequencing. Cancer Research, 2011, 71, 4443-4453.	0.9	331
4	EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Science Translational Medicine, 2014, 6, 244ra91.	12.4	304
5	Regional copy number–independent deregulation of transcription in cancer. Nature Genetics, 2006, 38, 1386-1396.	21.4	198
6	Oncoplastic Breast Surgery for Cancer: Analysis of 540 Consecutive Cases. Plastic and Reconstructive Surgery, 2010, 125, 454-462.	1.4	198
7	Management of Phyllodes Breast Tumors. Breast Journal, 2011, 17, 129-137.	1.0	169
8	Tissue-resident FOLR2+ macrophages associate with CD8+ TÂcell infiltration in human breast cancer. Cell, 2022, 185, 1189-1207.e25.	28.9	166
9	The Role of Nipple-Sparing Mastectomy in Breast Cancer. Plastic and Reconstructive Surgery, 2013, 131, 969-984.	1.4	157
10	Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific. Nature Immunology, 2018, 19, 885-897.	14.5	152
11	Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 5139-5144.	7.1	150
12	Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma <i>In situ</i> of the Breast. Clinical Cancer Research, 2008, 14, 1956-1965.	7.0	148
13	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncology, The, 2022, 23, 149-160.	10.7	148
14	ARF6–JIP3/4 regulate endosomal tubules for MT1-MMP exocytosis in cancer invasion. Journal of Cell Biology, 2015, 211, 339-358.	5.2	126
15	A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the Proliferation, Immune response and RNA splicing modules in breast cancer. Breast Cancer Research, 2008, 10, R93.	5.0	113
16	Changes in correlation between promoter methylation and gene expression in cancer. BMC Genomics, 2015, 16, 873.	2.8	113
17	The Molecular Subtype Classification Is a Determinant of Sentinel Node Positivity in Early Breast Carcinoma. PLoS ONE, 2011, 6, e20297.	2.5	105
18	Reconstruction after Conservative Treatment for Breast Cancer: Cosmetic Sequelae Classification Revisited. Plastic and Reconstructive Surgery, 2004, 114, 1743-1753.	1.4	103

#	Article	IF	CITATIONS
19	Luminal Progenitors Restrict Their Lineage Potential during Mammary Gland Development. PLoS Biology, 2015, 13, e1002069.	5.6	96
20	BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. Science Translational Medicine, 2020, 12, .	12.4	86
21	Characterization of the Recurrent 8p11-12 Amplicon Identifies PPAPDC1B, a Phosphatase Protein, as a New Therapeutic Target in Breast Cancer. Cancer Research, 2008, 68, 7165-7175.	0.9	83
22	Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL Blood, 2020, 135, 360-370.	1.4	80
23	8p22 MTUS1 Gene Product ATIP3 Is a Novel Anti-Mitotic Protein Underexpressed in Invasive Breast Carcinoma of Poor Prognosis. PLoS ONE, 2009, 4, e7239.	2.5	79
24	Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis. Genes and Development, 2015, 29, 2547-2562.	5.9	77
25	p63/MT1-MMP axis is required for in situ to invasive transition in basal-like breast cancer. Oncogene, 2016, 35, 344-357.	5.9	76
26	Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer. Annals of Oncology, 2017, 28, 2233-2240.	1.2	75
27	Thymic stromal lymphopoietin links keratinocytes and dendritic cell–derived IL-23 in patients with psoriasis. Journal of Allergy and Clinical Immunology, 2014, 134, 373-381.e4.	2.9	74
28	The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma. Molecular Oncology, 2015, 9, 657-674.	4.6	74
29	Pooling breast cancer datasets has a synergetic effect on classification performance and improves signature stability. BMC Genomics, 2008, 9, 375.	2.8	73
30	A prognostic DNA signature for T1T2 nodeâ€negative breast cancer patients. Genes Chromosomes and Cancer, 2010, 49, 1125-1134.	2.8	64
31	Visualizing Chromosomes as Transcriptome Correlation Maps: Evidence of Chromosomal Domains Containing Co-expressed Genes—A Study of 130 Invasive Ductal Breast Carcinomas. Cancer Research, 2005, 65, 1376-1383.	0.9	62
32	Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma. Breast Cancer Research and Treatment, 2018, 169, 295-304.	2.5	54
33	ESR1 gene amplification in breast cancer: a common phenomenon?. Nature Genetics, 2008, 40, 807-808.	21.4	53
34	Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Clinical Cancer Research, 2019, 25, 6731-6741.	7.0	53
35	Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy. PLoS ONE, 2020, 15, e0234191.	2.5	51
36	Breast Cancer Cell–Derived GM-CSF Licenses Regulatory Th2 Induction by Plasmacytoid Predendritic Cells in Aggressive Disease Subtypes. Cancer Research, 2015, 75, 2775-2787.	0.9	49

#	Article	IF	CITATIONS
37	Gastric metastasis of breast cancer: A single centre retrospective study. Digestive and Liver Disease, 2011, 43, 823-827.	0.9	45
38	Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers. Clinical Cancer Research, 2018, 24, 2605-2615.	7.0	45
39	A siRNA screen identifies RAD21 , EIF3H , CHRAC1 and TANC2 as driver genes within the 8q23, 8q24.3 and 17q23 amplicons in breast cancer with effects on cell growth, survival and transformation. Carcinogenesis, 2014, 35, 670-682.	2.8	44
40	Impact of Adjuvant Chemotherapy on Breast Cancer Survival: A Real-World Population. PLoS ONE, 2015, 10, e0132853.	2.5	44
41	Expression of Endoplasmic Reticulum Stress Proteins Is a Candidate Marker of Brain Metastasis in both ErbB-2+ and ErbB-2â^' Primary Breast Tumors. American Journal of Pathology, 2011, 179, 564-579.	3.8	42
42	Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort. British Journal of Cancer, 2016, 114, 44-52.	6.4	40
43	External Validation of Adjuvant! Online Breast Cancer Prognosis Tool. Prioritising Recommendations for Improvement. PLoS ONE, 2011, 6, e27446.	2.5	38
44	No evidence for TSLP pathway activity in human breast cancer. Oncolmmunology, 2016, 5, e1178438.	4.6	38
45	Preoperative radio-chemotherapy in early breast cancer patients: Long-term results of a phase II trial. Radiotherapy and Oncology, 2012, 102, 82-88.	0.6	37
46	Lymphovascular invasion has a significant prognostic impact in patients with early breast cancer, results from a large, national, multicenter, retrospective cohort study. ESMO Open, 2021, 6, 100316.	4.5	36
47	Determinants of return at work of breast cancer patients: results from the OPTISOINS01 French prospective study. BMJ Open, 2018, 8, e020276.	1.9	35
48	Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuantâ"¢ Microarray Based Assay. PLoS ONE, 2016, 11, e0146474.	2.5	34
49	Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers. Oncotarget, 2016, 7, 48206-48219.	1.8	32
50	Plastic surgery for breast conservation therapy: How to define the volume of the tumor bed for the boost?. European Journal of Surgical Oncology, 2014, 40, 830-834.	1.0	31
51	Breast cancer in young women: Pathologic features and molecular phenotype. Breast, 2016, 29, 109-116.	2.2	30
52	Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis. Oncolmmunology, 2016, 5, e1061176.	4.6	30
53	Surgical Margins and Adjuvant Therapies in Malignant Phyllodes Tumors of the Breast: A Multicenter Retrospective Study. Annals of Surgical Oncology, 2020, 27, 1818-1827.	1.5	28
54	Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy. PLoS ONE, 2015, 10, e0144359.	2.5	27

#	Article	IF	CITATIONS
55	Long-Term Prognostic Performance of Ki67 Rate in Early Stage, pT1-pT2, pN0, Invasive Breast Carcinoma. PLoS ONE, 2013, 8, e55901.	2.5	26
56	Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy. British Journal of Cancer, 2015, 113, 30-36.	6.4	25
57	A large retrospective multicenter study of vaginal melanomas. Melanoma Research, 2013, 23, 138-146.	1.2	24
58	Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients. Anticancer Research, 2009, 29, 1475-82.	1.1	24
59	Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies. Oncogene, 2014, 33, 619-631.	5.9	23
60	Axillary lymph node micrometastases decrease triple-negative early breast cancer survival. British Journal of Cancer, 2016, 115, 1024-1031.	6.4	23
61	A multivariate Th17 metagene for prognostic stratification in T cell non-inflamed triple negative breast cancer. Oncolmmunology, 2019, 8, e1624130.	4.6	23
62	Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancerÂpatients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status. European Journal of Cancer, 2017, 75, 323-332.	2.8	22
63	Use of deformable image fusion to allow better definition of tumor bed boost volume after oncoplastic breast surgery. Surgical Oncology, 2011, 20, e123-e125.	1.6	21
64	Implant breast reconstruction followed by radiotherapy: Can helical tomotherapy become a standard irradiation treatment?. Medical Dosimetry, 2012, 37, 425-431.	0.9	21
65	Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma. British Journal of Cancer, 2015, 113, 996-1002.	6.4	21
66	Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma. Modern Pathology, 2020, 33, 2198-2207.	5.5	21
67	Extensive pure ductal carcinoma in situ of the breast: Identification of predictors of associated infiltrating carcinoma and lymph node metastasis before immediate reconstructive surgery. Breast, 2014, 23, 97-103.	2.2	20
68	Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit. Breast Cancer Research and Treatment, 2019, 175, 379-387.	2.5	20
69	Histological grade concordance between diagnostic core biopsy and corresponding surgical specimen in HR-positive/HER2-negative breast carcinoma. British Journal of Cancer, 2014, 110, 2195-2200.	6.4	19
70	Neoadjuvant treatment: the future of patients with breast cancer. ESMO Open, 2018, 3, e000371.	4.5	19
71	Metastasis-suppressor NME1 controls the invasive switch of breast cancer by regulating MT1-MMP surface clearance. Oncogene, 2021, 40, 4019-4032.	5.9	19
72	Prediction of axillary lymph node status in male breast carcinoma. Annals of Oncology, 2013, 24, 370-376.	1.2	18

#	Article	IF	CITATIONS
73	Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer. Annals of Oncology, 2015, 26, 1704-1709.	1.2	18
74	Non-Sentinel Lymph Node Metastasis Prediction in Breast Cancer with Metastatic Sentinel Lymph Node: Impact of Molecular Subtypes Classification. PLoS ONE, 2012, 7, e47390.	2.5	18
75	Preoperative clinical pathway of breast cancer patients: determinants of compliance with EUSOMA quality indicators. British Journal of Cancer, 2017, 116, 1394-1401.	6.4	17
76	Innovative DIEP flap perfusion evaluation tool: Qualitative and quantitative analysis of indocyanine green-based fluorescence angiography with the SPY-Q proprietary software. PLoS ONE, 2019, 14, e0217698.	2.5	17
77	Respective Prognostic Value of Genomic Grade and Histological Proliferation Markers in Early Stage (pN0) Breast Carcinoma. PLoS ONE, 2012, 7, e35184.	2.5	17
78	Integrative DNA methylation and gene expression analysis to assess the universality of the CpG island methylator phenotype. Human Genomics, 2015, 9, 26.	2.9	16
79	Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study. Breast Cancer Research and Treatment, 2017, 162, 307-316.	2.5	16
80	Assessing reliability of intra-tumor heterogeneity estimates from single sample whole exome sequencing data. PLoS ONE, 2019, 14, e0224143.	2.5	16
81	Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact. Breast Cancer Research and Treatment, 2019, 173, 111-122.	2.5	16
82	Genomic Instability: A Stronger Prognostic Marker Than Proliferation for Early Stage Luminal Breast Carcinomas. PLoS ONE, 2013, 8, e76496.	2.5	16
83	Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore. British Journal of Cancer, 2021, 124, 1421-1427.	6.4	15
84	Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery. PLoS ONE, 2016, 11, e0159888.	2.5	15
85	Association of the number of sentinel lymph nodes harvested with survival in breast cancer. European Journal of Surgical Oncology, 2015, 41, 52-58.	1.0	14
86	Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models. British Journal of Cancer, 2015, 112, 912-917.	6.4	13
87	Impact of BRCA Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Cancers, 2020, 12, 3681.	3.7	13
88	Lack of prognostic impact of sentinel node micro-metastases in endocrine receptor-positive early breast cancer: results from a large multicenter cohortâ~†. ESMO Open, 2021, 6, 100151.	4.5	13
89	Epigenomic Alterations in Breast Carcinoma from Primary Tumor to Locoregional Recurrences. PLoS ONE, 2014, 9, e103986.	2.5	12
90	Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression. American Journal of Pathology, 2018, 188, 2378-2391.	3.8	12

#	Article	IF	CITATIONS
91	Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an â€~option' but an ethical obligation. ESMO Open, 2019, 4, e000515.	4.5	12
92	Theoretical and practical knowledge curriculum for European Breast Surgeons. European Journal of Surgical Oncology, 2020, 46, 717-736.	1.0	12
93	Circulating tumor cell detection and transcriptomic profiles in early breast cancer patients. Annals of Oncology, 2011, 22, 1458-1459.	1.2	11
94	The Impact of Poly Implant Prothèse Fraud on Breast Cancer Patients. Plastic and Reconstructive Surgery, 2013, 131, 690-695.	1.4	11
95	SMETHILLIUM: spatial normalization METHod for ILLumina InfinIUM HumanMethylation BeadChip. Bioinformatics, 2011, 27, 1693-1695.	4.1	10
96	Impact of time to local recurrence on the occurrence of metastasis in breast cancer patients treated with neoadjuvant chemotherapy: A random forest survival approach. PLoS ONE, 2019, 14, e0208807.	2.5	10
97	Impact of Metastasis Surgery and Alkylating-Agent-Based Chemotherapy on Outcomes of Metastatic Malignant Phyllodes Tumors: A Multicenter Retrospective Study. Annals of Surgical Oncology, 2020, 27, 1693-1699.	1.5	10
98	Pregnancy, fertility concerns and fertility preservation procedures in a national study of French breast cancer survivors. Reproductive BioMedicine Online, 2022, 44, 1031-1044.	2.4	10
99	Validation over time of a nomogram including HER2 status to predict the sentinel node positivity in early breast carcinoma. European Journal of Surgical Oncology, 2012, 38, 1211-1217.	1.0	9
100	A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways. PLoS ONE, 2016, 11, e0167397.	2.5	9
101	PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy. Cancers, 2021, 13, 746.	3.7	9
102	<scp>OTC</scp> deficiency in females: Phenotypeâ€genotype correlation based on a 130â€family cohort. Journal of Inherited Metabolic Disease, 2021, 44, 1235-1247.	3.6	9
103	Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application. PLoS ONE, 2016, 11, e0148957.	2.5	9
104	Outcome of oncoplastic breast-conserving surgery following bracketing wire localization for large breast cancer. Breast, 2015, 24, 370-375.	2.2	8
105	Tubular and mucinous breast cancer: results of a cohort of 917 patients. Tumori, 2019, 105, 55-62.	1.1	8
106	Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer. Oncolmmunology, 2020, 9, 1677427.	4.6	8
107	CloneSig can jointly infer intra-tumor heterogeneity and mutational signature activity in bulk tumor sequencing data. Nature Communications, 2021, 12, 5352.	12.8	8
108	Therapeutic escalation – De-escalation: Data from 15.508 early breast cancer treated with upfront surgery and sentinel lymph node biopsy (SLNB). Breast, 2017, 34, 24-33.	2.2	7

#	Article	IF	CITATIONS
109	New insight for pharmacogenomics studies from the transcriptional analysis of two large-scale cancer cell line panels. Scientific Reports, 2017, 7, 15126.	3.3	7
110	Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis. Breast Cancer Research and Treatment, 2017, 161, 73-81.	2.5	7
111	Domain-invariant features for mechanism of action prediction in a multi-cell-line drug screen. Bioinformatics, 2020, 36, 1607-1613.	4.1	7
112	HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast. Journal of Hematology and Oncology, 2021, 14, 143.	17.0	7
113	Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris. Translational Oncology, 2019, 12, 1557-1565.	3.7	6
114	The Prognostic Value of Lymph Node Involvement after Neoadjuvant Chemotherapy Is Different among Breast Cancer Subtypes. Cancers, 2021, 13, 171.	3.7	6
115	Prospective and Comparative Evaluation of the Toxicity of Adjuvant Concurrent Chemoradiotherapy After Neoadjuvant Chemotherapy for Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 425-429.	1.3	5
116	Chemosensitivity, tumor infiltrating lymphocytes (TILs), and survival of postpartum PABC patients treated by neoadjuvant chemotherapy. Breast, 2018, 42, 61-67.	2.2	5
117	Predicting Residual Cancer Burden In A Triple Negative Breast Cancer Cohort. , 2019, , .		5
118	The Presence of an In Situ Component on Pre-Treatment Biopsy Is Not Associated with Response to Neoadjuvant Chemotherapy for Breast Cancer. Cancers, 2021, 13, 235.	3.7	5
119	Time to Pregnancy, Obstetrical and Neonatal Outcomes after Breast Cancer: A Study from the Maternity Network for Young Breast Cancer Patients. Cancers, 2021, 13, 1070.	3.7	5
120	Quality of Life in an e-Cohort of Women Treated by Endocrine Therapy for Early Breast Cancer. Clinical Breast Cancer, 2022, 22, e352-e361.	2.4	5
121	Variation over time of the factors influencing return to work and work capacities after a diagnosis of breast cancer: a study on the behalf of the Seintinelles research network. Supportive Care in Cancer, 2022, 30, 5991-5999.	2.2	5
122	The French Early Breast Cancer Cohort (FRESH): A Resource for Breast Cancer Research and Evaluations of Oncology Practices Based on the French National Healthcare System Database (SNDS). Cancers, 2022, 14, 2671.	3.7	5
123	Prognostic factors for local recurrence following breast-conserving treatment in young women. Expert Review of Anticancer Therapy, 2010, 10, 1215-1227.	2.4	4
124	Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers. PLoS ONE, 2017, 12, e0169962.	2.5	4
125	Quality assurance in surgical trials: An improvement is needed. Gynecologic Oncology, 2020, 157, 570-571.	1.4	4
126	Adjuvant chemotherapy for breast cancer after preoperative chemotherapy: A propensity score matched analysis. PLoS ONE, 2020, 15, e0234173.	2.5	4

#	Article	IF	CITATIONS
127	Patterns of Sequelae in Women with a History of Localized Breast Cancer: Results from the French VICAN Survey. Cancers, 2021, 13, 1161.	3.7	4
128	Breast Cancer (BC) Is a Window of Opportunity for Smoking Cessation: Results of a Retrospective Analysis of 1234 BC Survivors in Follow-Up Consultation. Cancers, 2021, 13, 2423.	3.7	4
129	Sentinel lymph node biopsy validation for large tumors. International Journal of Surgery, 2017, 48, 275-280.	2.7	3
130	Helical tomotherapy for patients presented with implant breast reconstruction in case of adjuvant breast cancer radiotherapy: A single center experience. Breast Journal, 2020, 26, 1436-1438.	1.0	3
131	No Impact of Smoking Status on Breast Cancer Tumor Infiltrating Lymphocytes, Response to Neoadjuvant Chemotherapy and Prognosis. Cancers, 2020, 12, 2943.	3.7	3
132	Mesh Erosion After Anterior Prosthetic Reinforcement by Vaginal Route: Risk Factors and Management. Journal of Gynecologic Surgery, 2008, 24, 1-10.	0.1	2
133	Le point sur les signatures moléculaires dans le cancer du sein. Oncologie, 2010, 12, 263-268.	0.7	2
134	HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens. Cancers, 2021, 13, 370.	3.7	2
135	Breast Magnetic Resonance Image Analysis for Surgeons Using Virtual Reality: A Comparative Study. JCO Clinical Cancer Informatics, 2021, 5, 1127-1133.	2.1	2
136	Prevalent versus incident breast cancers: benefits of clinical and radiological monitoring in women with pathogenic BRCA1/2 variants. European Journal of Human Genetics, 2022, , .	2.8	2
137	Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy. Cancers, 2022, 14, 1331.	3.7	2
138	Digital phenotyping in young breast cancer patients treated with neoadjuvant chemotherapy (the) Tj ETQq0 0 0	rgBT/Ove 2.6	rlock 10 Tf 50
139	Skin Lesions after Prophylactic Mastectomy and Immediate Reconstruction. Plastic and Reconstructive Surgery - Global Open, 2013, 1, e82.	0.6	1
140	Long-term Follow-up for Inflammatory Breast Cancer Patients: Institute Curie Experience. International Journal of Radiation Oncology Biology Physics, 2010, 78, S158-S159.	0.8	0
141	Literature review assessing time to adjuvant chemotherapy and long term oncological outcomes between patients undergoing simple mastectomy and immediate reconstruction. European Journal of Surgical Oncology, 2017, 43, S21-S22.	1.0	0
142	Benefit of adjuvant systemic therapies in HR+ HER2- pT1ab node-negative breast carcinomas. Annals of Oncology, 2018, 29, viii63.	1.2	0
143	JAK-STAT PATHWAY AND EPIGENETIC REGULATORS ARE CRITICAL PLAYERS IN BI-ALCL PATHOGENESIS?. Hematological Oncology, 2019, 37, 201-201.	1.7	0
144	Factors Associated With the Discussion of Fertility Preservation in a Cohort of 1,357 Young Breast Cancer Patients Receiving Chemotherapy. Frontiers in Oncology, 2021, 11, 701620.	2.8	0

#	Article	IF	CITATIONS
145	Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL): The Lymphoma Study Association (LYSA) Registry Data. Blood, 2019, 134, 4021-4021.	1.4	0
146	Title is missing!. , 2020, 15, e0234191.		0
147	Title is missing!. , 2020, 15, e0234191.		0
148	Title is missing!. , 2020, 15, e0234191.		0
149	Title is missing!. , 2020, 15, e0234191.		0
150	No Impact of Seasonality of Diagnoses on Baseline Tumor Immune Infiltration, Response to Treatment, and Prognosis in BC Patients Treated with NAC. Cancers, 2022, 14, 3080.	3.7	0